ABSTRACT
Fertility study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na), a novel neutrophil elastase inhibitor, was conducted in Sprague-Dawley (SD) rats. ONO-5046.Na was administered intravenously at doses of 18.75, 37.5 and 75 mg/kg/day to male rats from 64 prior to mating, through the mating period and until necropsy, and to female rats from 15 days prior to mating until Day 7 of gestation, in order to examine its effects on fertility and reproductive performance of males and females and the development of their fetuses. There were no changes attributable to ONO-5046.Na in general signs, body weight, food consumption or autopsy findings in males and females. No drug-related changes were observed in estrous cycles, copulation and fertility indices in males and females. Pituitary weight of dams was decreased in each of the ONO-5046.Na treated groups, but no histopathological changes were observed in the pituitary. In the cesarean section findings in dams, ONO-5046.Na had no effects on the number of corpola lutea, the number of live fetuses, the implantation ratio, the resorbed and dead fetus ratio, fetal or placental weight, or the incidences of external, skeletal or visceral anomalies of the fetuses. From these results, it is considered that the NOAEL of ONO-5046.Na is 75 mg/kg/day for general and reproductive toxicity in males and females and for developmental toxicity in their fetuses.
Subject(s)
Embryonic and Fetal Development/drug effects , Fertility/drug effects , Glycine/analogs & derivatives , Serine Proteinase Inhibitors/toxicity , Sulfonamides/toxicity , Animals , Body Weight/drug effects , Female , Glycine/administration & dosage , Glycine/toxicity , Injections, Intravenous , Male , No-Observed-Adverse-Effect Level , Organ Size/drug effects , Pituitary Gland/anatomy & histology , Pregnancy , Rats , Rats, Sprague-Dawley , Serine Proteinase Inhibitors/administration & dosage , Sulfonamides/administration & dosageABSTRACT
Prenatal and postnatal toxicity of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na), a novel inhibitor of human neutrophil elastase, was studied in Sprague-Dawley (SD) rats. ONO-5046.Na was injected intravenously at doses of 0, 18.75, 37.5 and 75 mg/kg/day to pregnant rats from day 7 of pregnancy to day 20 after delivery. All pregnant rats were allowed to deliver naturally for postnatal examination of their offspring. No adverse effects on dams were observed in clinical signs, body weight change, food consumption, pregnant, delivery or lactating performances. ONO-5046.Na did not affect the postnatal development of offspring, including birth index, survival index, physical and functional development, motor activity, emotionality, learning ability and reproductive performance. From these results, it is considered that the NOAEL of ONO-5046.Na is 75 mg/kg/day for dams and their offspring.
Subject(s)
Animals, Newborn/growth & development , Glycine/analogs & derivatives , Pregnancy, Animal/drug effects , Serine Proteinase Inhibitors/toxicity , Sulfonamides/toxicity , Animals , Behavior, Animal/drug effects , Body Weight/drug effects , Female , Glycine/administration & dosage , Glycine/toxicity , Injections, Intravenous , Learning/drug effects , Male , No-Observed-Adverse-Effect Level , Organ Size/drug effects , Pregnancy , Rats , Rats, Sprague-Dawley , Reproduction/drug effects , Serine Proteinase Inhibitors/administration & dosage , Sulfonamides/administration & dosageABSTRACT
Teratogenicity of sodium N[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino]benzoyl] aminoacetate tetrahydrate (ONO-5046.Na), a novel inhibitor of human neutrophil elastase, was studied. ONO-5046.Na was injected intravenously at doses of 0, 7.5, 15 and 30 mg/kg/day to pregnant Kbl: NZW rabbits from day 6 to day 18 of pregnancy. All female rabbits were sacrificed on day 29 of pregnancy and their fetuses were examined. There were no clinical signs or death attributable to ONO-5046.Na. One dam in the control group and 3 dams in the 30 mg/kg/day group aborted. Body weight gain in the 15 and 20 mg/kg/day groups and food intake in the 30 mg/kg/day group were decreased during the administration period. These changes had recovered by the end of the study. Kidney weight was increased in the 30 mg/kg/day group. There were no effects of ONO-5046.Na in necropsy findings at cesarean section in dams at any dose levels. Developmental toxicity of ONO-5046.Na was not found at any dose levels. From these results, it is considered that the NOAEL of ONO-5046.Na is 7.5 mg/kg/day for pregnant animals and 30 mg/kg/day for fetuses.
Subject(s)
Embryonic and Fetal Development/drug effects , Glycine/analogs & derivatives , Pregnancy, Animal/drug effects , Serine Proteinase Inhibitors/toxicity , Sulfonamides/toxicity , Animals , Body Weight/drug effects , Eating/drug effects , Female , Glycine/administration & dosage , Glycine/toxicity , Injections, Intravenous , No-Observed-Adverse-Effect Level , Pregnancy , Rabbits , Serine Proteinase Inhibitors/administration & dosage , Sulfonamides/administration & dosageABSTRACT
A fertility study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in Sprague-Dawley (SD) rats. ONO-1101 was administered intravenously to males from the 64th day before mating until necropsy, and to females from 15th day before mating until day 7 of gestation, at a dose level of 0 (control), 25, 50 or 100 mg/kg/day. On day 20 of gestation, all dams were sacrificed and their fetuses were examined. In the 100 mg/kg/day group, hypoactivity, clonic convulsion, bradypnea/apnea and redish lacrimation were observed after administration in both sexes, and 3 males and 2 females died. Reddish lacrimation was occasionally seen in males at late stage of the treatment period in 50 mg/kg/day group. In the 100 mg/kg/day group, body weight gain suppressed in females from the premating through the gestation period, and food consumption decreased in females during the premating period, and mean thymus weight decreased in males. ONO-1101 did not affect estrous cycle, copulatory or fertility in both sexes or external, skeletal or visceral features of the fetuses. From the above results, it is estimated that the no-toxic dose level of ONO-1101 under these experimental conditions is 50 mg/kg/day for general toxicity in parents, and 100 mg/kg/day for the reproductive performance in parents and for the development of fetuses.
Subject(s)
Adrenergic beta-Antagonists/toxicity , Fertility/drug effects , Morpholines/toxicity , Urea/analogs & derivatives , Adrenergic beta-Antagonists/administration & dosage , Animals , Body Weight/drug effects , Dose-Response Relationship, Drug , Eating/drug effects , Embryonic and Fetal Development/drug effects , Female , Fetus/drug effects , Maternal-Fetal Exchange , Morpholines/administration & dosage , Organ Size/drug effects , Pregnancy , Rats , Rats, Sprague-Dawley , Urea/administration & dosage , Urea/toxicityABSTRACT
A teratogenicity study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in Sprague-Dawley (SD) rats. ONO-1101 was administered intravenously at a dose level of 0 (control), 25, 50 or 100 mg/kg/day to pregnant rats from day 7 to 17 of gestation, and effects of ONO-1101 on dams, fetuses and their offspring, were examined. In the 100 mg/kg/day group, hypoactivity, bradypnea, reddish lacrimation, clonic convulsion and loss of righting reflex were observed and 2 animals died. Food consumption in the 100 mg/kg/day group decreased during the treatment period. No drug-related changes were observed in dams for their body weights, necropsy findings or organ weights. Decrease in placental weight was seen in the 100 mg/kg/day group, but no effect was found in fetal weight. ONO-1101 had no effects on delivery and lactation. On day 4 after birth, viability of offspring were decrease in the 50 or 100 mg/kg/day group, and body weight of males were decreased in the 100 mg/kg/day group, but no change caused by the treatment was observed in growth of offspring thereafter. On skeletal examination in offsprings culled on day 4 after birth, increase in the incidence of unossificated talus were seen in the 50 or 100 mg/kg/day group. But no drug-related anomalies were observed in external, skeletal or visceral findings in fetuses. It was not also found any influence of ONO-1101 on external differentiations, functional, behavioral or learning abilities or reproductive performance in offspring. From the above results, it is estimated that the no-toxic dose level of ONO-1101 under these experimental conditions is 50 mg/kg/day for dams, and 25 mg/kg/day for their offspring.
Subject(s)
Adrenergic beta-Antagonists/toxicity , Embryonic and Fetal Development/drug effects , Fetus/drug effects , Morpholines/toxicity , Pregnancy, Animal/drug effects , Urea/analogs & derivatives , Adrenergic beta-Antagonists/administration & dosage , Animals , Body Weight/drug effects , Dose-Response Relationship, Drug , Eating/drug effects , Female , Fetal Organ Maturity/drug effects , Injections, Intravenous , Male , Maternal-Fetal Exchange , Morpholines/administration & dosage , Organ Size/drug effects , Pregnancy , Prenatal Exposure Delayed Effects , Rats , Rats, Sprague-Dawley , Reproduction/drug effects , Urea/administration & dosage , Urea/toxicityABSTRACT
A teratogenicity study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in KAR:NZW rabbits. ONO-1101 was administered intravenously at a dose level of 0 (control), 25, 50 or 100 mg/kg/day to pregnant rabbit from day 6 to 18 of gestation to examine the effects on dams and fetuses. Death occurred on 3 animals in the 100 mg/kg/day group and one animal in the 50 mg/kg/day group during the treatment period. Hypoactivity, bradypnea/apnea and clonic convulsion after administration was observed in animal dosed 100 mg/kg/day. No maternal effects were seen on body weight, food consumption, necropsy findings or organ weights. External, skeletal and visceral findings revealed no adverse effects of ONO-1101 on fetuses. From the above results, it is estimated that the no-toxic dose level of ONO-1101 under these experimental conditions is 25 mg/kg/day for dams and 100 mg/kg for fetuses.
Subject(s)
Adrenergic beta-Antagonists/toxicity , Embryonic and Fetal Development/drug effects , Fetus/drug effects , Morpholines/toxicity , Pregnancy, Animal/drug effects , Urea/analogs & derivatives , Adrenergic beta-Antagonists/administration & dosage , Animals , Body Weight/drug effects , Dose-Response Relationship, Drug , Eating/drug effects , Female , Injections, Intravenous , Maternal-Fetal Exchange , Morpholines/administration & dosage , Organ Size/drug effects , Pregnancy , Rabbits , Urea/administration & dosage , Urea/toxicityABSTRACT
A perinatal and postnatal study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in Sprague-Dawley(SD) rats. ONO-1101 was administered intravenously at a dose level of 0 (control), 25, 50 or 100 mg/kg/day from day 17 of gestation to day 20 after parturition to examine the effects on pregnancy, delivery, lactation and the effects on postnatal growth and development of offspring. In the 100 mg/kg/day group, hypoactivity, reddish lacrimation, clonic convulsion and bradypnea/apnea were observed after administration and 5 animals died in the treatment period, and body weight on day 21 and food consumption on day 14-21 of dam at weaning were lower than control group. In the 50 mg/kg/day group, reddish lacrimation was occasionally seen in some animals. ONO-1101 had no effects on pregnancy, delivery, lactation and necropsy findings or organ weights of dams. In the 100 mg/kg/day group, viability of offspring on day 4 after birth decreased and body weight gain of the suckling suppressed, but those changes recovered after weaning. On the skeletal examination of offspring culled on day 4 after birth, decrease in the mean number of osiffied phalanges of hindpaw and increase in the incidence of unossified talus bone were seen in the 100 mg/kg/day group, however, no delay of ossification was found form the weanling. There were no influence of ONO-1101 on external differentiation, functional, behavioral or learning abilities or reproductive performance in offspring. From the above results, it is estimated that the no-toxic dose level of ONO-1101 under these experimental conditions is 50 mg/kg/day for dam and offspring.
